Terrestrial Bio today shared new preclinical data demonstrating the translatability of its patch technology for delivering GLP-1 therapies.
Boston-based Terrestrial (formerly Vaxess Technologies) shared findings at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. Outcomes showed the translatability of the proprietary Tacterra MAP platform to deliver next-generation obesity therapies that involve co-delivery of an amylin analog and a GLP-1 receptor agonist (GLP-1 RA).
The company’s microarray patch (MAP) technology features a soluble microarray with tips that gradually dissolve into the body after removal. These tips release their payload of therapeutics over time, mimicking how natural infections interact with the body.
MAP technology removes sharps, eliminates the need for refrigeration and enables self-administration for user comfort. Clinical findings shared at ADA last year highlighted the platform’s capabilities in GLP-1 delivery.
In its study shared at ADA 2026, Terrestrial used CagriSema. The combination of GLP-1 RA semaglutide and amylin RA cagrilintide served as a model to evaluate in vitro and in vivo performance. Investigators delivered MAP and injections in Göttingen minipigs. They injected liquid preparations of drug substance separately into subcutaneous tissue. Meanwhile Tacterra delivered CagriSema via a single MAP administration to the skin.
Terrestrial reported that the co-delivery via a single patch achieved comparable bioavailability to the subcutaneous injection. This provides a patient-friendly alternative to dual-chamber autoinjectors for combination therapies. Additionally, Tacterra MAPs significantly improved the stability of the therapeutics, supporting cold chain-free storage.
Rachel Sha, CEO of Terrestrial Bio, said:
“Codelivery of amylin analogs with GLP-1 RAs is of interest due to their synergistic therapeutic benefits for Type 2 diabetes and obesity, but administering these active pharmaceutical ingredients together has traditionally required a complex and expensive dual-chambered injector due to instability when coformulated. We’ve built a single, shelf-stable microarray patch that codelivers both therapies without coformulation. Patients will be able to simply apply the patch, and receive their medication in a pain free and easy way.”
